|Last Price$13.35||Day Change (%)-13.76%|
|Open Price$15.57||Day Change ($)-2.13|
|Day Range12.07–15.58||52-Week Range3.55–15.58|
As of Wed 9/28/2016 5:14:00 PM | USD
Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress
Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma
European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
Governor Doug Ducey Will Address Arizona’s Life Science Innovation Community at the Peak of Arizona Bioscience Week During the 11th Annual AZBio Awards
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.